Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel and starting abiraterone acetate revealed 5 adverse prognostic factors: hemoglobin < 12 g/dL, > 10 metastases, ECOG performance st...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical genitourinary cancer Vol. 15; no. 4; pp. 502 - 508
Main Authors:	Van Praet, Charles, Rottey, Sylvie, Van Hende, Fransien, Pelgrims, Gino, Demey, Wim, Van Aelst, Filip, Wynendaele, Wim, Gil, Thierry, Schatteman, Peter, Filleul, Bertrand, Schallier, Denis, Machiels, Jean-Pascal, Schrijvers, Dirk, Everaert, Els, D'Hondt, Lionel, Werbrouck, Patrick, Vermeij, Joanna, Mebis, Jeroen, Clausse, Marylene, Rasschaert, Marika, Van Erps, Joanna, Verheezen, Jolanda, Van Haverbeke, Jan, Goeminne, Jean-Charles, Lumen, Nicolaas
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-08-2017
Subjects:	Abiraterone Acetate - therapeutic use Aged Chemotherapy Humans Male Prednisone - therapeutic use Prognosis Proportional Hazards Models Prostatic neoplasms Prostatic Neoplasms, Castration-Resistant - drug therapy Retrospective Studies ROC Curve Steroids Survival Survival Analysis Taxoids - therapeutic use Treatment Outcome Chemotherapy Prognosis Prostatic neoplasms Survival Steroids
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!